# Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis

> **NCT05828225** · PHASE1 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 9 (estimated)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **DRUG:** CD19 CAR-T cells injection

## Key facts

- **NCT ID:** NCT05828225
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-30
- **Primary completion:** 2026-04-20
- **Final completion:** 2026-04-20
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2023-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05828225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05828225, "Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05828225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*